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Abstract
 
The role of the hematopoietic lineage-restricted minor histocompatibility (H) antigen HA-1 in
renal allograft tolerance was explored. We obtained peripheral blood samples from three recipients
of histocompatibility leukocyte antigen (HLA)–matched, HA-1–mismatched renal transplants,
one of which had discontinued immunosuppression 
 
 
 
30 yr ago while sustaining normal kidney
function. Peripheral blood mononuclear cells (PBMCs) were injected into the footpads of severe
combined immunodeficiency mice to measure human delayed type hypersensitivity (DTH)
responses. All three patients manifested regulated DTH responses to HA-1
 
H
 
 peptide. By differ-
ential tetramer staining intensities, we observed two distinct minor H antigen HA-1–specific
CD8
 
 
 
 T cell subsets. The one that stained dimly had the characteristics of a T regulatory (T
 
R
 
)
cell and produced interleukin (IL) 10 and/or transforming growth factor (TGF) 
 
 
 
. These HA-1–
specific T
 
R
 
 cells coexisted with bright tetramer-binding CD8
 
 
 
 T effector (T
 
E
 
) cells. The CD8
 
 
 
T
 
E
 
 cells mediated HA-1–specific DTH and produced interferon-
 
 
 
. Suppression of these T
 
E
 
functions by T
 
R
 
 cells was TGF
 
 
 
, IL-10, and cytotoxic T lymphocyte–associated antigen 4
dependent. In addition, HA-1 microchimerism was detected in two recipients, primarily in the
dendritic cell fraction of the PBMCs. This is the first demonstration of coexisting CD8
 
 
 
 memory
T
 
R
 
 and T
 
E
 
 cells, both specific for the same HA-1 antigen, in the context of renal allograft tolerance.
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Introduction
 
The basis of immunologic tolerance remains largely a mystery
 
 
 
50 yr after its discovery by Owen (1). Inhibition of poten-
tially pathogenic self-reactive T cells by CD4
 
 
 
 T regulatory
(T
 
R
 
) cells has been proposed as one of the major mechanisms
for the establishment of peripheral tolerance to autoantigens
(2, 3) and for the persistence of certain forms of chronic
infection (4). Transplantation tolerance studies in rodents
have suggested that certain donor-derived alloantigens, which
stimulate T cell–dependent graft rejection, could also trigger
T
 
R
 
 cell responses that promote allograft acceptance (5, 6).
However, the T cell receptor specificity of T
 
R
 
 cells and
what drives their development remain largely unknown.
The hematopoietic-specific minor histocompatibility (H)
antigen HA-1 is a nine–amino acid peptide encoded by
a diallelic gene on human chromosome 19 (7, 8). The
immunogenic HA-1 T cell epitope differs from its allelic
counterpart by one amino acid at position 3 (i.e., VLHD-
DLLEA
 
→
 
VLRDDLLEA; reference 7). Although nonameric
peptides of both the HA-1
 
H
 
 and the HA-1
 
R
 
 alleles bind to
HLA-A2, the HA-1
 
R
 
 allele fails to be expressed at the cell
surface in the context of HLA-A2 (7). The HA-1
 
H
 
 peptide
is presented at the cell surface and induces strong HLA-A2–
restricted CTLs (9, 10). The HA-1 difference between
HLA-A2
 
 
 
 bone marrow donor and recipient, when the
recipient is H/R or H/H, and the donor is R/R, can lead
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to the development of acute GVHD (11). HA-1–specific
mismatch GVHD occurs early after bone marrow trans-
plant when residual recipient APCs can still provide the
target antigen, triggering bystander destruction of skin and
other epithelial tissues (12).
HLA-identical siblings and HLA-matched cadaver donors
are the ideal renal transplant donors and indeed have the
best outcomes long-term. Yet, in the case of a minor H an-
tigen such as HA-1, the efflux of large numbers of “passen-
ger leukocytes” (13) early after transplantation might induce
activation of donor-specific cytotoxic and proinflammatory
T effector (T
 
E
 
) cells that could trigger bystander destruction
of the kidney epithelium. In contrast, long-term persistence
of donor-derived microchimerism (14) might lead to chronic
suppression of host T
 
E
 
 cells (15, 16). Here, we demonstrate
the coexistence of CD8
 
 
 
 T
 
R
 
 and T
 
E
 
 cells, both specific for
the same hematopoietic-specific minor H antigen, HA-1,
together with dendritic cell microchimerism in the context
of solid organ transplant tolerance.
 
Materials and Methods
 
Animals.
 
CB-17 SCID mice were purchased from Harlan
Sprague Dawley, Inc. or were bred locally. All animals were
housed and treated in accordance with National Institutes of
Health guidelines.
 
Reagents, Antibodies, and Antigens.
 
All antibodies used in flow
cytometry were purchased from BD Biosciences. Neutralizing
anti–human CD152 (CTLA-4) mAb was purchased from Anti-
body Solutions. IL-10– and TGF
 
 
 
-neutralizing antibodies were
purchased from R&D Systems. HA-1H, HA-1R, CMVpp65
(NLVPMVATV), and HY (FIDSYICQV) peptides were all syn-
thesized and purified (purity 
 
 
 
94%) at the University of Wiscon-
sin-Madison Biotechnology facility. HA-1A2 tetramers were pre-
pared as described previously (11). All other reagents were
purchased from Sigma-Aldrich.
 
Patients.
 
Patient I (tolerant; 32 yr off immunosuppressive
drugs; HLA A 2, 3; B7, 12/44; DR1, 4; and HA-1 R/R) re-
ceived a kidney transplant from her HLA-identical sister (HA-
1H/H) in 1967. Patient II (HLA: A1, 2; B8, 27; DR4, 17; and
HA-1R/R) received a kidney transplant from her HLA-identical
HA-1–mismatched brother (HA-1H/R) in 1996. Patient III
(HLA: A2, 24; B35, 57; DR4, 11; and HA-1R/R) received an
HLA-identical, HA-1–mismatched (HA-1: H/R) kidney trans-
plant from a sister in 1988, lost the graft 10 yr later because of
chronic allograft nephropathy, and received a second HA-1–mis-
matched transplant from a 5-HLA antigen-matched sister (HLA:
A2, 24; B44, 57; DR4, 11; and HA-1H/R) in 2000. Control
patient IV (HLA: A2, 24, B13, 35; DR7, 8; and HA-1: R/R)
received a kidney transplant from her HLA- and HA-1(R/R)–
identical brother in 1997. Patients II and IV are taking azathio-
prine and cyclosporine, and patient III is taking prednisone, tac-
rolimus, and mycophenolate mofetil. All patients currently have
excellent graft function, with serum creatinine 
 
 
 
1.4 mg/dL.
 
Flow Cytometric Analysis and Cell Sorting.
 
For flow cytometric
analysis, we used a FACSCalibur™ instrument with CELLQuest™
software (BD Biosciences). Flow sorting was performed at 4
 
 
 
C
using FACSVantage™ (Becton Dickinson). After sorting, tet-
ramer-positive cells were incubated at 37
 
 
 
C, 5% CO
 
2
 
 in 10%
FCS-containing RPMI 1640 for 1–2 h, washed with PBS, and
used in DTH or ELISPOT assay.
 
Trans Vivo DTH Analysis.
 
The trans vivo DTH assay was
used as described previously (17) to detect donor antigen-linked
suppression of human recall antigen responses to tetanus toxoid
(TT), EBV antigen, or to EBV-transformed B-lymphoblastoid
cell lines (B-LCLs). To test for regulated DTH responses to HA-1,
7–9 
 
 
 
 10
 
6
 
 cryopreserved PBMCs were coinjected into a CB17
SCID mouse footpad with 1 
 
 
 
g HA-1H peptide and 25 
 
 
 
g of ei-
ther control or anticytokine (TGF
 
 
 
 or IL-10) neutralizing anti-
bodies. Swelling response was measured 24 h later by using a
thickness gauge.
 
Detection of IFN-
 
 
 
–secreting Cells by ELISPOT Assays.
 
IFN-
 
 
 
ELISPOT was performed as described previously (18), except
that: (a) tetramer-binding cell-depleted PBMCs (TDPs, 125,000)
were used as APCs; (b) 1,000 flow-sorted HA-1
 
A2-high
 
 or 30,000
HA-1
 
A2-low
 
 cells were used as responders; and (c) 1 
 
 
 
g/well HA-
1H peptide was used as antigen. In some wells, 10 
 
 
 
g anti-TGF
 
 
 
,
anti–IL-10, or anti–CTLA-4 blocking antibodies were added.
 
Detection of Microchimerism.
 
Genomic DNA from PBMCs
was amplified by PCR with HA-1 H sequence-specific primers
(SSPs); the products were separated and transferred to nylon
membrane. After hybridization with a digoxigenin-11-ddUTP–
labeled oligonucleotide probe, HA-1 H–specific signal was de-
tected by chemiluminescence. Microchimerism in leukocyte sub-
sets was determined by nested PCR using HA-1 allele-specific
primer sets (unpublished data).
 
Online Supplemental Material. 
 
The online supplemental ma-
terial contains three figures, as well as additional Materials and
Methods and Results. Fig. S1 shows TGF
 
  
 
response of CD8
 
 
 
tetramer-low T cells in overnight culture with APCs and pep-
tides. Fig. S2 shows surface phenotype and cytotoxic function of
CD8 T cell lines derived by in vitro culture of HA-1/A2 tet-
ramer-low and HA-1/A2 tetramer-high T cells. Fig. S3 shows
surface phenotype of HA-1/A2 tetramer-low and HA-1/A2 tet-
ramer-high CD8 T cells in flow cytometry histograms. Online
supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20031012/DC1.
 
Results and Discussion
 
We tested DTH responses to the HA-1
 
H
 
 antigen in the
footpads of SCID mice. PBMCs were obtained from 4
HLA-A2
 
 
 
, HA-1-R/R recipients of primary renal trans-
plants from HLA-identical sibling donors, including one
(patient III), who was tested 3 yr after a second transplant
from a sibling matched for HLA-A, -DR, and for 1 (out of
2) HLA-B alleles. Patient I stopped taking azathioprine and
prednisone 5 yr after transplant (19) and remained off im-
munosuppressive drugs with excellent graft function for
 
 
 
30 yr (17). The other three allograft recipients are still tak-
ing immunosuppressive drugs. As shown in Fig. 1 A, all
PBMCs tested had weak swelling responses to the HA-1
 
H
 
peptide, either in the presence of PBS (unpublished data) or
a control IgG. In the three patients who received a HA-1
 
H
 
–
mismatched renal transplant, DTH responses to HA-1
 
H
 
peptide were observed when neutralizing antibodies to ei-
ther IL-10 (patient II), TGF
 
 
 
 (III), or both (I) were coin-
jected. The control recipient, patient IV, who received a
HA-1–matched renal transplant, remained unresponsive to
HA-1
 
H
 
 after cytokine neutralization (Fig. 1 A). The HA-
1
 
H
 
–responsive T
 
R
 
 cells also demonstrated “linked suppres-
sion” of DTH response to a recall antigen (Fig. 1 B). Al- 
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though PBMCs of patients I–III had strong DTH responses
to TT or EBV antigen alone, these responses were markedly
suppressed in the presence of coinjected HA-1
 
H
 
 peptide. In
contrast, patient IV’s PBMCs retained a strong response to
recall antigens in the presence of HA-1
 
H
 
 (Fig. 1 B).
The DTH response of tolerant patient I to HA-1
 
H
 
 was
donor specific and dose dependent, with no anti-HY (third
party) or anti-HA-1
 
R
 
 (self) peptide responses seen in the
presence of neutralizing anti-TGF
 
 
 
 antibodies (Fig. 1 C).
 
Regulator and Effector HA-1–specific T Cells Can Be Distin-
guished by HLA Tetramer Staining Intensity.
 
The recovery
of a strong DTH response to HA-1
 
H
 
 by cytokine neutral-
ization suggested that PBMCs obtained 36 yr after renal
transplant contained not one, but two distinct functional
subtypes of HA-1
 
H
 
–specific T cells as follows: one mediat-
ing DTH, the other producing TGF
 
 
 
 and/or IL-10,
thereby suppressing DTH. Two types of minor H antigen-
specific T cells were distinguishable by HA-1
 
A2
 
 tetramer
(11) staining intensity. Fig. 2 A shows that the majority of
the small CD8
 
 
 
 T lymphocytes that stained positively
(1.22 
 
 
 
 0.46%; 
 
n
 
 
 
  
 
5) showed low tetramer staining (HA-
1
 
A2-low
 
; mean fluorescent index 
 
  
 
58 
 
 
 
 25). A small por-
tion (0.056 
 
 
 
 0.027%; 
 
n
 
 
 
  
 
5) of the CD8
 
 
 
 T cells showed
bright staining (HA-1
 
A2-high
 
; mean fluorescent index 
 
 
 
720 
 
 
 
 160). Next, sorted HA-1
 
A2-high
 
 and HA-1
 
A2-low
 
 CD8
 
 
 
T cells were tested for DTH response to HA-1
 
H
 
 peptide. As
shown in Fig. 2 B, control mouse footpad injections of
PBMCs depleted of tetramer-binding CD8
 
 
 
cells (TDPs)
plus HA-1
 
H
 
 peptide caused a weak swelling. In the presence
of TDP and peptide, 10
 
3
 
 HA-1
 
A2 high
 
 CD8  T cells caused
a strong DTH response, whereas 3   104 HA-1A2-low CD8 
T cells failed to mediate a detectable swelling response.
When combined with the HA-1A2-low cells, the DTH re-
sponse of HA-1A2-high cells was suppressed. TDP still con-
tained CMV-reactive CD8  T cells, as indicated by a
strong DTH response to CMVpp65 (Fig. 2 B). Addition of
tetramer-sorted, HA-1A2-low CD8  T cells had no effect on
the DTH response to CMVpp65 (Fig. 2 B), which con-
firmed that, in the absence of cognate ligand for the CD8 
TR cell, there is no linked suppression of a third party anti-
viral CD8 TE cell response.
The suppression by HA-1A2-low CD8  T cells of the
HA-1–specific DTH response of HA-1A2-high CD8  T
cells was reversed by addition of TGF  neutralizing anti-
body, but not by a control IgG. The magnitude of the re-
covered DTH response was dependent on the dose of
added HA-1A2-high T cells (Fig. 2 C). Furthermore, the
HA-1H peptide, but not CMVpp65, induced approxi-
mately twofold increased expression of intracellular
TGF 1 over the background level in sorted HA-1A2-low
CD8  T cells during overnight culture with autologous
APCs (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20031012/DC1). To see if the CD8 
TR cells could respond to endogenous HA-1 antigen at lev-
els normally expressed by donor leukocytes, we used a
linked suppression system similar to that shown in Fig. 1
B, except that B-LCLs were used as a source of both EBV
and endogenous minor H antigen. We found similarly
strong DTH responses to autologous B-LCLs and to EBV
antigen; however, a markedly reduced response to donor
B-LCLs was observed (Fig. 2 D, left). This result was likely
due to donor-specific CD8 T cell–mediated suppression
Figure 1. Minor H antigen HA-1–mismatched renal transplant
recipients have regulated DTH responses to HA-1H peptide.
(A) PBMCs were tested for DTH responses to H peptide with
control IgG, anti-TGF , and anti–IL-10 antibodies. Donor HA-1
typing, years after transplant, and patient status are indicated (gray
background, tolerant; white background, continuous immuno-
suppression). Bars represent mean   SE of 2–3 determinations.
(B) PBMCs were injected with a recall antigen (TT or EBV)
alone, or with recall antigen plus H peptide. NT, not tested. (C)
Patient I PBMCs were tested for DTH responses in the presence
or absence of anti-TGF 1 neutralizing antibody, with varying
doses of HA-1H (left), HY (center), and HA-1R peptide (right).Minor H Antigen-specific CD8 T Regulatory Cells in Allograft Tolerance 1020
because CD8-depleted PBMCs made equally strong DTH
responses to both donor and autologous B-LCLs. Addi-
tion of flow-sorted HA-1A2-low CD8  T cells completely
suppressed the DTH response to donor, but not autol-
ogous, B-LCLs. Similar numbers of tetramer-negative
CD8  T cells failed to mediate significant suppression of
DTH (Fig. 2 D, right).
Tetramer-sorted CD8  T cells from patient I were
placed in long-term culture with autologous HA-1H–
pulsed DCs. Tetramer-low CTL lines expressed normal
membrane levels of TCR   and CD8, but required a 100-
fold higher HA-1H peptide level to sensitize autologous
B-LCLs for lysis, as compared with tetramer-high CTL
(Fig. S2, available at http://www.jem.org/cgi/content/
full/jem.20031012/DC1).
Suppression of In Vitro IFN-  Production by Addition of TR
to TE Cells. We questioned whether the HA-1A2-high T
cells contained IFN-  producers and whether the HA-
1A2-low cells could suppress the IFN production. Tetramer-
based flow sorting of PBMCs was performed and in vi-
tro  IFN-  responses of the sorted cells were measured
ELISPOT. In wells plated with 1.25   105 TDP as a
source of APCs or with tetramer-sorted T cells alone (un-
published data),  5 IFN-  spots/well were detected in the
presence of 10  g/ml of HA-1H peptide. When 103 HA-
1A2-high CD8  T cells were stimulated with HA-1 peptide
in the presence of APCs, substantial production of IFN- 
(Fig. 3,  200 spots/well) was observed. In contrast, 3  
104 HA-1A2-low T cells failed to produce IFN-  upon HA-1
peptide–specific stimulation. The same TR cells completely
inhibited HA-1–specific IFN-  production by cocultured
HA-1A2-high CD8 T cells (Fig. 3). This in vitro inhibition
effect, unlike the suppression of the in vivo DTH response,
was largely resistant to antibodies neutralizing TGF  or IL-10
(10% recovery of response), but was sensitive to CTLA-4
antibody blockade (Fig. 3, 70% recovery). Anti–CTLA-4
blocking antibody could also reverse DTH unresponsive-
ness of whole PBMCs to HA-1H (unpublished data), indi-
cating an important role of CTLA-4 in suppressor cell
function both in vivo and in vitro.
Figure 2. Antagonistic effects
of HA-1 tetramer-high and -low
binding CD8 T cells on the HA-
1H–specific DTH response of
patient I and induction of linked
suppression by tetramer-low
CD8 T cells. (A, left) Forward
scatter versus CD8 staining. R1
indicates gating on CD8  small
lymphocytes. (right) Detection
of HA-1H–specific CD8  T
cells in the R1 gate using HLA
tetramers. The percentage of total
CD8  T cells in each subset, HA-1A2–low and HA-1A2–high, is indicated. This histo-
gram is representative of five experiments. (B) Flow-sorted HA-1A2–high (high, 103)
and HA-1A2–low (low, 3   104) CD8  tetramer-binding T cells plus tetramer-
depleted PBMCs (TDPs, 7   106) were injected separately or along with either
HA-1H or CMVpp65 control peptide. The results shown are mean   SD of three
separate experiments. (C) Varying numbers of HA-1A2–high tetramer-binding CD8 
T cells (0   103 cells) were tested for DTH response to HA-1H in the presence
of 3   104 low tetramer-binding cells and 7   106 TDP. Either rabbit IgG (open
squares) or anti–TGF- 1 antibody (closed squares) was added before footpad injection.
(D) Unfractionated PBMCs (8   106) or PBMCs depleted of CD8  T cells (8   106)
were injected along with EBV antigen (EBV, white bars), recipient (gray bars), or
donor (black bars) B-LCLs (2   10 5cells). Shown are the mean   SE of n   3 DTH
determinations. To restore donor-specific DTH suppression in CD8-depleted
PBMCs, 9   103 HA-1A2–low CD8  T cells or 9   103 HA-1A2–negative CD8  T
cells were added along with either recipient or donor B-LCL.Cai et al. Brief Definitive Report 1021
HA-1H–specific T Cells Are Predominantly of the Effector
Memory Phenotype. Further phenotype analysis of the HA-
1–specific TR and TE cells is shown in Fig. S3 (available at
http://www.jem.org/cgi/content/full/jem.20031012/DC1)
and Table I. Although the tetramer-negative CD8  T cells
from the tolerant patient were predominantly CD28 , 78%
of the TR cells and 68% of the TE cells were CD28 . The
TR cells consisted mainly of CD45RO  CD62L  CCR7 
T cells of the memory effector type (20). The tetramerhigh
CD8  T E subset did contain a significant component of
central memory T cells (Table I, 27%), but like the TR cells,
were predominantly memory effector type.
Microchimerism as a Possible Source of Ongoing HA-1 Anti-
gen Stimulation. We hypothesized that a source of ongo-
ing antigen stimulation in the HA-1H–regulated patients
would account for the HA-1H–specific CD8  T cells that
regulate the DTH response. To identify a continuous
source of HA-1 antigen in vivo, we tested for HA-1 H mi-
crochimerism. DNA extracted from the PBMCs of patients
I and II were analyzed for the presence of HA-1H genomic
DNA. Microchimerism corresponding to the lower limit
of detection of a PCR/SSP assay (a donor cell frequency of
1/104) was confirmed by sequence-specific oligonucleotide
probe in patient I (Fig. 4 A). Next, a nested PCR assay
using genomic DNA from flow-sorted T cells, B cells,
monocytes, DCs (CD11c  plus CD123 ), and from in
vitro–cultured monocyte-derived DCs was performed (Fig.
4 B). The strongest positive signals for HA-1H genomic
DNA were detected in the DC-enriched subsets of both
patients, despite the low cell recovery in this fraction. A
weak positive signal was also detected in T cells and in cul-
tured DCs from tolerant patient I. The HA-1H DNA sig-
nals in B cell and monocyte subsets were below the level of
detection (1 in 105 cells) in both patients.
Here, we describe in a patient with  30 yr tolerance to
a renal transplant the coexistence of CD8  TR cells with
TE cells of identical specificity, but differing in strength of
binding to cognate peptide/MHC ligand. These findings
Figure 3. Suppression of IFN-  response of HA-1A2–high by HA-1A2–
low tetramer-binding CD8  T cells. TDP, flow-sorted HA-1 tetramer-
low (low, 3   104 cells/well), and tetramer-high (high, 103 cells/well)
CD8  T cells were tested separately or in combination for response to
HA-1H (n   3 wells). Control responses of sorted T cells alone to H
peptide (no TDP added) were  5 spots/well.
Table I.  Phenotyping of Tetramer HA-1A2 Low, High, and Negative CD8  T Cells by Flow Cytometric Analysis
  CD8 T cell subset CD45 RO  CD8 T cells 
HA-1A2 subsets CTLA-4  CD28  CD45RO  CD62L  CCR-7  CCR-7 
%% % %% %
Low 77 78 96 92 4 96
High 50 68 90 82 27 73
Negative 24 24 49 92 1 99
Cell surface expression was analyzed for all markers except CTLA-4 (intracellular). Data are summarized from the flow histograms (Fig. S3). Values
shown are representative of two separate experiments.
Figure 4. PCR analysis reveals HA-1 microchimerism in the dendritic
cell subset of PBMCs. (A) HA-1H  DNA was detected by PCR/SSP
(top) and sequence-specific oligonucleotide probe/Southern Blot assay
(bottom left) in whole PBMCs of patient I. DNA from HA-1 H/H and
R/R individuals were used as controls. A titration of H/H into R/R
genomic DNA (right lanes) is shown. Lanes a and b represent DNA samples
derived from 80 and 40   106 PBMCs of patient I. (B) Cell subsets were
isolated from 300   106 PBMCs of patients I and II. HA-1H  DNA in
each cell fraction was detected by nested PCR. Cell fractions are as follows:
M, monocytes (6.0   106); T, T lymphocytes (15.0   106); B, B lym-
phocytes (1.6   106); DC, dendritic cells (0.33   106); and cDC, in vitro
cultured monocyte-derived DC (0.75   106). Right panels indicate the
standards (H/H→R/R DNA) for each experiment. NT, not tested.Minor H Antigen-specific CD8 T Regulatory Cells in Allograft Tolerance 1022
provide an explanation for the retention of strong but
tightly regulated T cell memory responses to the donor mi-
nor H antigen, HA-1. Coexistence of TGF -producing
CD8  T R cells with IFN- –producing CD8  T E cells,
each specific for different HIV epitopes, has been described
in chronic HIV infection (21). A similar homeostatic
equilibrium, involving CD4 CD25  T R cells and CD4 
CD25  TE cells has been described for the chronic phase of
Leishmania major infection in mice (4).
The in vivo expansion of antigen-specific memory CD8 
T cells with low binding to cognate peptide/MHC ligand
and regulatory function is a novel finding. Chronic low
avidity engagement of TCR with agonist peptide/MHC
complexes in vivo has been shown to render memory
CD4  T cells anergic (22). Indeed, we found that HA-1A2-low
CD8  T cells proliferated poorly in response to HA-1 pep-
tide-pulsed autologous DC, IL-7, and IL-2 stimulation in
vitro. In contrast, HA-1A2-high CD8  cytotoxic TE cell lines
showed excellent in vitro growth (unpublished data). These
results argue that the TR cells are anergic memory effector T
cells. Why antigen restimulation in vivo does not give a
selective advantage to high avidity TE cells is not clear.
CTLA-4 has been shown to attenuate strong signals gener-
ated through the TCR, while permitting the generation of
weaker TCR signals (23). This regulatory role of CTLA-4
at the immune synapse has been proposed as a means of
broadening the TCR repertoire recruited in response to an-
tigen stimulation by limiting the selective advantage of high
affinity over low affinity TCR  clones (24). Indeed, the
majority ( 75%) of the HA-1A2-low (TR) cells, and half of
the TE cells coexpressed CTLA-4 (Table I and Fig. S3). Be-
cause anti–CTLA-4 blocking antibody could reverse TR
cell–mediated suppression both in vivo and in vitro, we
propose that CTLA-4 plays a dual role in HA-1H–specific
CD8  cell responses, favoring growth and function of TR
cells, while restraining that of TE cells.
As yet, no MHC class II–restricted T cell epitopes en-
coded by the HA-1 gene have been defined. Thus, we can-
not rule out the possible involvement of HA-1–specific
CD4  CD25  TR cells at some phase of the host regula-
tory T cell response. The fact that CD8 T cell–depleted
PBMCs of the tolerant patient failed to manifest linked
suppression of DTH to donor B-LCLs would suggest that
CD4  TR cells were not required. However, it is clear that
CD4  TR cells do mediate regulation of DTH and skin al-
lograft rejection in MHC-mismatched, tolerant renal al-
lograft recipients (6, 25, 26).
The hematopoietic-specific HA-1 antigen is not ex-
pressed by kidney parenchymal cells. This suggests an indi-
rect role for HA-1–specific TR cells in maintaining renal
transplant tolerance. All three HA-1–mismatched patients
displayed linked suppression of DTH responses to a third
party antigen when HA-1H was present (Fig. 1 B). There-
fore, we speculate that the colocalization of HA-1–specific
TR cells with donor-derived DCs (Fig. 4 B) may propagate
infectious tolerance to antigens shed by the kidney paren-
chyma and presented by the same DCs to other minor
H-specific T cells. The fact that low numbers of HA-1–
specific CD8  T R cells could mediate linked suppression
when donor leukocytes were used as the source of endoge-
nous antigen (Fig. 2 D) supports this speculation. Although
we cannot rule out the “null” hypothesis (i.e., that HA-1
microchimerism in blood DC precursors is epiphenome-
nal), we also cannot exclude the alternative possibility that
microchimerism sustains minor H antigen-specific CD8  T
memory cells as has been suggested recently (27). Based on
the HA-1 typing of patient I’s daughter born 20 yr before
transplant, as well as the deduced HA-1 heterozygosity of
her parents, either the transplant donor (H/H), maternal
(H/R), or fetal (H/R) exposures may have contributed to
her HA-1 microchimerism.
If the HA-1 H  DCs do contact the recipient’s HA-1–
specific T cells in vivo, it is noteworthy that the CD8  TR
cells were found in the small lymphocyte population (Fig. 2
A), and thus by scatter profile were not typical of effector
memory T cells that have recently encountered antigen. In
this regard, the encounter of plasmacytoid DC with alloge-
neic CD8  T cells has been found to induce an IL-10–pro-
ducing TR cell with a smaller size (based on forward scat-
ter) than that of antigen-activated TE cells (28).
In conclusion, our findings indicate that lifelong periph-
eral tolerance to an organ allograft can be achieved without
the loss of immunologic memory to donor antigen. If these
results can be confirmed in other tolerant transplant recipi-
ents, it suggests a new rationale for clinical tolerance strate-
gies, taking advantage of the inhibition of memory CD8 TE
cells by regulatory T cells with low avidity for the same
cognate antigen.
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